Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...
News Medical on MSN17h
AI model identifies potential risk genes for Parkinson's diseaseResearchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...
The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...
Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...
In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...
Advanced artificial intelligence genetics models have been successfully applied to Parkinson’s disease at CCGC.
Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...
Hosted on MSN3d
Parkinson's disease could be treated by FDA-approved cancer drug after major research breakthroughA major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...
Brain implants to repair Parkinson’s damage being developed by University of Cambridge researchers
Brain implants that could help repair the pathways damaged by Parkinson’s disease are being developed by University of ...
Scientists from the Institute of Nano Science and Technology (INST) Mohali, an autonomous institute of the Department of Science and Technology, announced a targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback